The Motley Fool

Why I think AstraZeneca should be in your 2019 share portfolio

Amidst the broader market volatility, investors are likely to be more selective as to which stocks to add to their portfolio in 2019. If you believe in holding shares for the long term, I’d suggest that you take a closer look at AstraZeneca (LSE: AZN) shares as part of your healthcare portfolio.

Year-to-date, AZN’s share price is up about 10%, despite the market volatility. Let’s take a closer look at the fundamentals that are supporting the strong performance of the shares.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Robust earnings

The company is one of the largest, most innovative pharmaceutical companies globally. Its latest earnings release in November showed a strong balance sheet and positive outlook going into 2019. Chief executive Pascal Soriot confirmed expectations that the company is to grow both organically and possibly through acquisitions — which it can afford thanks to its cash flow. Analysts are now looking for a 10%+ earnings per share (EPS) increase in the New Year.

In addition to a robust balance sheet and growing profits, the dividend yield of 3.3% makes it a worthwhile pick for risk-averse income investors who know that they can compound their returns through reinvesting dividends.

Broad pipeline

The firm’s R&D and manufacturing focus lies in cancer (oncology), cardiovascular, gastrointestinal, infection, neuroscience, and respiratory, and inflammation segments. Lynparza, Tagrisso, and Brilinta are new drugs that analysts expect to contribute to the top line.

It has several prospective drug launches in the cancer, metabolism and respiratory areas, such as Imfinzi — prescribed against lung cancer. And it is exploring new avenues for growth too. In November it announced a partnership with the Belgian Biocartis Group — a molecular diagnostics company  for obtaining lung cancer diagnostic biomarker results. Its cancer focus has seen it selling its anaesthetics medicines, as well as its antibiotics division, to raise cash for what it sees as its core areas.

What could derail the shares?

On December 11, the UK parliament will vote on the Prime Minister’s proposed Brexit deal. If the government loses the vote, the country will face more uncertainty — and that would be likely to that negatively affect the FTSE, the pound and possibly AstraZeneca shares, in spite of its strength so far this year.

Like most large pharmaceutical companies, it also faces continuous risks from generic drugs competition, especially for its Nexium, Crestor, and Seroquel brands. That means some investors may see a P/E ratio of 25 as a bit rich. Personally, I think its pipeline is strong enough to offset any threat to the bottom line.

If the share price does suffer in 2019, I would expect to see yet another takeover bid from Pfizer. In 2014, the board rejected a £55-per-share offer made by the US company but AZN’s drive to become a leader in oncology treatments means many analysts both in the UK and the US would not be surprised to see yet another offer from its erstwhile suitor.

The bottom line on the shares

AstraZeneca is a fundamentally sound company with a good track record of R&D and commercialisation success – two factors that translate into a strong balance sheet and double-digit bottom line growth next year. With a beta of around 0.65 (meaning it is one of those stocks that are less volatile than the broader market), I think it could be a strong pick for another downleg or a possible bear market in 2019.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

tezcang has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.